Karine Lélu, et al.
Journal of Hepatology, April 2015, Volume 62, Supplement 2, Page S205 – Download the article
Publication
TG1050, a Novel Immunotherapeutic to Treat Chronic Hepatitis B, can Control HBsAg and Provoke HBsAg Seroconversion in HBV-Persistent Mouse Models
Par alcyon|2019-07-02T17:38:07+02:00avril 30th, 2015|Publication, TG1050|Commentaires fermés sur TG1050, a Novel Immunotherapeutic to Treat Chronic Hepatitis B, can Control HBsAg and Provoke HBsAg Seroconversion in HBV-Persistent Mouse Models
À propos de l'auteur : alcyon
Articles similaires
- Design of an Innovative Model to Improve Anticancer Therapeutic Treatment Based on a Vascularized 3D Organoids Derived from Patients’ Lung Tumors for the Purpose of Precision Medicine
Design of an Innovative Model to Improve Anticancer Therapeutic Treatment Based on a Vascularized 3D Organoids Derived from Patients’ Lung Tumors for the Purpose of Precision Medicine
- BT-001, an oncolytic Vaccinia virus armed with a Treg-depletion-optimized recombinant human anti-CTLA4 antibody and GM-CSF to target the tumor microenvironment
BT-001, an oncolytic Vaccinia virus armed with a Treg-depletion-optimized recombinant human anti-CTLA4 antibody and GM-CSF to target the tumor microenvironment
- Meta analysis of two phase 1b randomized, double blind, placebo controlled clinical trials of the HBV therapeutic vaccines TG1050 and T101 developed in Europe/Canada or China
Meta analysis of two phase 1b randomized, double blind, placebo controlled clinical trials of the HBV therapeutic vaccines TG1050 and T101 developed in Europe/Canada or China